27 results about "Dexamethasone" patented technology

This invention discloses an isoflavone compound, its preparation method, and its applications. The compounds are derived by directional esterification modification of all phenolic hydroxyl groups with allyloxycarbonyl chloride, o-chlorobenzoyl chloride, or cinnamoyl chloride, using 4',7-dihydroxyisoflavone or 4',5,7-trihydroxyisoflavone as the parent nucleus. The invention also provides a mild and efficient preparation method for these compounds and confirms their significant anti-inflammatory pharmacological activity. Pharmacological studies show that compounds B and E, in particular, exhibit excellent in vitro and in vivo anti-inflammatory activity, with compound E showing superior activity compared to the positive control drug dexamethasone. These compounds can be used to prepare drugs for treating inflammatory diseases such as pneumonia and colitis.

This invention discloses a method for inducing pluripotent stem cells to differentiate into skin keratinocytes and its culture medium, solving problems such as long differentiation cycles, low yields, insufficient purity, and animal-derived contamination in existing technologies. The first stage uses medium I containing FGF2 and tanshinone IIA to promote mesodermal differentiation. The second stage uses medium II containing BMP4, EGF, dexamethasone, and PVA to regulate and synergistically induce the BMP / ERK signaling pathway. The final stage uses medium III for expansion culture, obtaining fibroblasts with a purity >99% within 20 days. This method is non-invasive, simple, and low-cost, with potential for large-scale production. The obtained cells can be used for skin regeneration, disease modeling, drug screening, and clinical treatment, demonstrating significant medical application and industrial transformation value.

This invention discloses the application of agar-agar polysaccharides in the preparation of products with bone density-improving effects. The agar-agar polysaccharides are obtained from agar-agar as raw material through acid extraction, alcohol precipitation, dialysis, and ion exchange chromatography purification, with a weight-average molecular weight range of 1500-5000 Da. This invention applies agar-agar polysaccharides to the preparation of products with bone density-improving effects, including food, health products, or pharmaceuticals; particularly, it can be used to prepare functional cereal foods. The agar-agar polysaccharides of this invention have an ameliorative effect on bone density loss in a dexamethasone-induced zebrafish osteoporosis model, can enhance the activity of alkaline phosphatase (ALP) in zebrafish, and promote osteoblast differentiation.

Provided herein are methods of treating and / or managing cancer, comprising administering to a patient Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Additionally, provided herein are methods of treating and / or managing cancer, comprising administering to a patient Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a second active agent selected from the group consisting of an anti-CD20 antibody, an HDAC inhibitor, a proteasome inhibitor, an anti-CD38 antibody, an anti-SLAMF7 antibody, a nuclear export inhibitor, a BCL-2 inhibitor, and an immune checkpoint inhibitor. Also provided herein are combination therapies for treating and / or managing cancer, further comprising dexamethasone as a third active agent.

The present application relates to a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops and its preparation method and application, belong to the new auxiliary material and new dosage form technical field of drug preparation combined treatment, a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops, including temperature-sensitive gel solution and the fluorinated nanomedicine uniformly dispersed in the temperature-sensitive gel solution;The fluorinated nanomedicine is the nanometer assembly formed by intermolecular interaction co-assembly of dexamethasone and fluorinated side chain prodrug;The structural formula of the fluorinated side chain prodrug is as shown below.The temperature-sensitive hydrogel eye drops of the present application further regulate iron death by synergistic anti-inflammatory and antioxidant effects, provide new strategy for treating dry eye.

The utility model discloses an online detection device of dexamethasone sodium phosphate injection intermediate belongs to pharmacy detection field, including support, install ultraviolet spectrophotometer equipment on the support to setting liquid dilution bucket on the support, the liquid dilution bucket discharge opening is connected with the hose, and the bottom end of hose is connected with the pipe head, and the support is provided with the drive mechanism that drives the pipe head to move up and down, is provided with the cuvette on ultraviolet spectrophotometer equipment, and the support is provided with two clamps symmetrically, and two clamps all are pasted in the outer wall of cuvette, through the cooperation of above each device, through the gear drive first rack and second rack lift, to drive the pipe head realizes accurate lifting, and the cooperation clamp holds the cuvette, distinguishes from manual dosing, and the cuvette is fixed in the exactly same position every time, makes liquid to be able to follow the pipe head accurate and enter the inside of cuvette, greatly improves the detection efficiency.

The application belongs to the field of pharmaceutical chemistry, and particularly relates to a glucocorticoid prodrug, a preparation method and application thereof. The glucocorticoid prodrug has low solubility, is suitable for preparation of a long-acting sustained-release preparation, and compared with existing dexamethasone palmitate preparations on the market, the compound of the application provides more excellent long-acting sustained-release effect, while effectively reducing systemic drug exposure, thereby minimizing or avoiding systemic side effects possibly caused by glucocorticoids.

The present application belongs to the technical field of biological medicine, and particularly relates to a pyruvate preparation for asthma treatment and a preparation method thereof. The pyruvate preparation comprises the following components in parts by weight: 10-12 parts of pyruvate, 10-12 parts of sodium chloride, 0.5-1 part of citric acid, and 500 parts of water for injection; and the pH of the pyruvate preparation is 6-7. The pyruvate preparation is used for daily management of asthma patients, can control the increase of inflammatory cells such as eosinophilic granulocyte, reduce inflammatory reaction, and thus achieve the purpose of inhibiting asthma. The effect of the pyruvate preparation is close to that of the same kind of hormone drug dexamethasone, and the pyruvate preparation can achieve the treatment purpose while reducing the dependence of patients on hormone drugs and side effects.

The application belongs to the technical field of medicine, and particularly relates to application of mulberry leaf ethyl acetate extract in preparation of products for treating, improving or preventing sarcopenia. The application establishes a sarcopenia model by using dexamethasone. It is proved by tests that the mulberry leaf ethyl acetate extract has the effects of reducing the content of MURF1 in serum, increasing the relative weights of gastrocnemius muscle, soleus muscle, tibialis anterior muscle and quadriceps muscle of mice, reducing the SOD activity in liver tissue, increasing the CAT activity, inhibiting the expression of GDF-8 protein in muscle, improving the pathological state of gastrocnemius muscle and reducing muscle fiber atrophy. The above results show that the mulberry leaf ethyl acetate extract plays an anti-sarcopenia effect through multi-target and multi-pathway synergistic effect, and provides a new technical scheme for drug treatment and functional food development of sarcopenia, and has a good application prospect.

This disclosure relates to a method for establishing a HepaRG-based differentiated liver 3D microsphere model and its applications. Specifically, this disclosure provides a chemically defined differentiation medium formulation that does not require DMSO and contains hepatocyte growth factor, dexamethasone, and hepatoprotectin M. Using this medium, HepaRG cells can be efficiently induced to form compact, long-lived 3D microspheres in ultra-low adsorption 96-well plates or in conjunction with high-throughput 3D printing technology. After differentiation and maturation, the model can stably express hepatocyte markers, key drug-metabolizing enzymes, and nuclear receptors at high levels. The liver 3D microsphere model established by this disclosure can effectively simulate hepatocyte function in vivo and is suitable for high-throughput drug hepatotoxicity screening. The results show a high degree of consistency with clinical hepatotoxicity data, and it has important application value in the field of drug safety evaluation.

The application discloses a human soft tissue filling material and a preparation method thereof, wherein the human soft tissue filling material comprises the following components in parts by weight: 45-75 parts of cross-linked zinc hyaluronate gel, 30-50 parts of bioglass, 5-15 parts of hydroxyapatite, 0.5-5 parts of glycerol, 0.1-0.25 parts of lidocaine hydrochloride and 0.1-0.7 parts of dexamethasone. The preparation method of the human soft tissue filling material is simple in process, convenient in operation and low in cost, and the prepared human soft tissue filling material is slow in degradation speed, good in antibacterial property and biocompatibility and difficult to be displaced.

The application discloses a method for evaluating the concentration and combined effect of a glucocorticoid mixture in a sample, and relates to the technical field of biology. The method analyzes the relationship among concentration, time and effect according to a two-phase mechanism of receptor-ligand binding dissociation kinetics, innovatively constructs a two-phase response surface model of dexamethasone concentration, time and effect (dexamethasone model), and introduces a two-phase response surface model of glucocorticoid mixture concentration, time and effect in a sample (sample model) with the index of combined effect. The contributions of time and concentration to the effect and the two-phase complex scene are comprehensively considered, and the reasonable and scientific evaluation of the concentration and combined effect of the glucocorticoid mixture in the sample is realized without losing accuracy by combining the Levenberg-Marquardt algorithm with the Jacobian matrix method. The method provides a solution for evaluating the concentration (in terms of dexamethasone) of the glucocorticoid mixture in a sample and analyzing the combined effect based on a cell strain.

Provided is to a compound or a pharmaceutically acceptable salt thereof for use in a composition for rejuvenating aged microglia, and a pharmaceutical composition for preventing or treating brain diseases containing the same. Also disclosed is the use of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof to restore the phagocytic function of microglia that has been impaired by dexamethasone, thereby providing a rejuvenation composition for aged microglia that can be usefully applied as a pharmaceutical composition for preventing or treating brain diseases including neurodegenerative diseases, neuroinflammatory diseases, depression, and neuropsychiatric disorders.

This invention discloses a method for detecting the encapsulation efficiency of dexamethasone palmitate injection, belonging to the technical field of encapsulation efficiency detection. The method involves mixing dexamethasone palmitate injection with a solvent for extraction; the dexamethasone palmitate injection comprises a fat emulsion and free dexamethasone palmitate; after extraction, the fat emulsion and free dexamethasone palmitate are separated, and the encapsulation efficiency is calculated by quantitative analysis using HPLC; the polarity of the solvent is similar to that of the dexamethasone palmitate. This invention utilizes the principle of "like dissolves like" to develop a method for determining the encapsulation efficiency of dexamethasone palmitate injection extracted with an organic solvent. This method effectively separates the fat emulsion from the free dexamethasone palmitate while ensuring that the structure of the fat emulsion is not damaged during the measurement process, thus avoiding falsely low encapsulation efficiency due to drug leakage.

本发明属于生物医药技术领域，具体涉及一种小分子化合物在制备改善肌肉衰减药物中的应用。本发明使用地塞米松诱导小鼠成肌细胞C2C12产生肌肉衰减模型，通过CCK8活性检测，Western Blot检测肌少症相关蛋白表达情况。通过以上检测指标综合评估小分子化合物在制备改善肌肉衰减的作用。实验结果证明，小分子化合物SY‑4（Syringaresinol，丁香脂素）和 / 或SY‑35（Vomifoliol，吐叶醇）对细胞无明显毒性作用，同时显著降低了肌肉降解蛋白（Murf1）的表达量，并提升了肌肉合成蛋白（MyOD）的表达水平，具有很好的肌肉衰减治疗潜力，可以用于制备改善肌肉衰减药物。

The application discloses an in-vivo drug delivery device, and relates to the technical field of medical intervention instruments.The main body of the in-vivo drug delivery device is made of PEG powder and 50:50 proportion of PLGA medical degradable high-molecular material, is formed through a salt pore forming process, and is internally provided with uniform and slow-release pores.The size can be adapted to different target blood vessels, the device is implanted into a lesion blood-supplying blood vessel through an intervention mode, and the drug loading formula can be flexibly adjusted according to diseases, and heparin and dexamethasone are added to prevent thrombosis and suppress inflammation.The in-vivo drug delivery device can realize 1-3 month controllable slow release of drugs, accurately delivers the drugs to a lesion at a high concentration, solves the problems of poor curative effect and large toxic and side effects of systemic drug delivery, is suitable for local treatment of malignant tumors and refractory chronic inflammation, and finally is completely degraded without residue, and does not need secondary operation.The in-vivo drug delivery device has the advantages of simple structure, flexible drug loading, good biocompatibility, wide clinical application range, and effectively makes up for the technical defects of existing local drug delivery devices.

The present application belongs to the technical field of interventional medical instruments, and relates to a drug-coated balloon for realizing time sequence release of two drugs in cooperation, and a preparation method and application thereof. The present application provides, in view of the defects of the existing drug-coated balloon, a drug-coated balloon with a three-layer structure of an inner layer drug coating, an intermediate adhesive layer and an outer layer drug coating from inside to outside on the balloon substrate, and time sequence precise release of two drugs in cooperation of an inhibitor and an anti-inflammatory agent: dexamethasone is used for rapid anti-inflammatory response to the early inflammation peak of vascular repair, and rapamycin / everolimus is used for long-acting inhibition of smooth muscle proliferation to realize long-term prevention of restenosis; through the design of the degradable carrier and the adhesive layer, the outer layer is fast-released, the inner layer is slow-released, the coating is firm, and the whole process is degradable, so that the effectiveness and safety of vascular intervention treatment are improved from the root.

The present application relates to the technical field of animal model construction, and relates to a fetal origin atherosclerosis susceptible model and a construction method and application thereof.The construction method of the fetal origin atherosclerosis susceptible model comprises the following steps: S1, selecting healthy pregnant ApoE- / - mice, subcutaneously injecting dexamethasone twice a day at 16-17 days of pregnancy, the injection amount of dexamethasone is 0.6-0.8 mg / kg of the body weight of the pregnant female mouse, and the pregnant female mouse is free to eat; S2, the pregnant female mouse naturally gives birth to F1 generation, the male and female offspring are weaned and separated into cages at 3-4 weeks after birth, and continue to be normally fed until 6-7 weeks after birth, and then high-fat high-cholesterol feed is given to feed until 18-19 weeks; the fetal origin atherosclerosis susceptible model is obtained.The present application successfully constructs the fetal origin atherosclerosis susceptible model by injecting dexamethasone at a specific time, and the atherosclerosis lesion of the model presents a significant aggravation effect.

This invention relates to the field of biomedical technology, and in particular to an animal model of COPD combined with sarcopenia and the application of mesenchymal stem cells in the treatment of this disease. The method of constructing the model includes the following steps: (1) Pre-stimulation stage: On the first day of modeling, lipopolysaccharide (LPS) is administered via airway nebulization to initiate airway inflammation, and continuous exposure to cigarette smoke is implemented from the first day of modeling; during this period, LPS is administered again on the 10th to 14th day of modeling to enhance the persistence of inflammation; (2) Partial phenotype confirmation stage: Lung function tests or their alternative indicators are performed on the animals after the pre-stimulation ends; (3) While continuing to implement smoke exposure, dexamethasone proteolytic load and mechanical load regulation treatment are introduced simultaneously for the enrolled animals until the total modeling time reaches 4 to 6 weeks; (4) The endpoint airflow limitation index, weight loss and muscle strength loss index are detected, and the animals are deemed to have successfully constructed the model if they simultaneously meet the corresponding thresholds.

The application provides a drought-resistant synergist for improving plant stress resistance and a preparation method thereof, and belongs to the technical field of garden tree planting, and the preparation method of the drought-resistant synergist comprises the following steps: (1) dissolving nano zinc oxide metal particles in an aqueous solution, and preparing a suspension liquid by using an ultrasonic device; (2) adding vitamins, dexamethasone and acetic acid into the suspension liquid in sequence to prepare the drought-resistant synergist. The drought-resistant synergist is used in the cultivation process of Ilex verticillata container seedlings, compared with the pure water control, the survival time of the Ilex verticillata container seedlings treated by the drought-resistant synergist is prolonged, and the preparation method of the drought-resistant synergist is simple and easy to popularize and use.

This invention discloses the application of glycyrrhizin in the preparation of drugs for the treatment or prevention of chronic obstructive pulmonary disease (COPD), relating to the field of biomedical technology. Specifically, this invention discloses the application of glycyrrhizin or its pharmaceutically acceptable salts in the preparation of drugs for the treatment and / or prevention of COPD. Through drug screening and in vitro and in vivo experiments, this invention is the first to demonstrate that glycyrrhizin can not only inhibit inflammation, but also has a better effect than glycyrrhizic acid, a natural product derived from licorice. Furthermore, this invention functionally demonstrates that glycyrrhizin can significantly improve the decline in lung function and reduce airway hyperresponsiveness in COPD model animals; pathologically, it confirms that it can effectively reduce pulmonary inflammatory infiltration and tissue damage; and molecularly, it demonstrates that glycyrrhizin has the effect of inhibiting the expression of inflammatory factors, and its effect is better than that of the positive control drug dexamethasone, showing great promise for its application in the treatment of COPD.

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases, comprising an extract of Brassica juncea as an active ingredient. Inhibitory activity against myotube cell atrophy, a muscle anabolic factor expression promoting activity, and an effect of recovering from dexamethasone-induced enhancement of muscle cell catabolism and inhibition of anabolism of the Brassica juncea extract have been analyzed, and the effects of the Brassica juncea extract on recovery of reduced muscle tissue size, weight and muscle fiber size, biostability, a serum LDH level recovery effect, and an effect of reducing CK and creatinine levels in animal models have been analyzed, and thus it has been identified that the Brassica juncea extract can be used for preventing or treating sarcopenia or muscle atrophy.

The application provides a kit for culturing osteosarcoma organoids, the kit comprising a special culture medium, a sample dissociation digestive solution and a digestion termination solution, the special culture medium being based on a basic culture medium and adding dexamethasone, glycerophosphate disodium salt and calcium chloride, the osteosarcoma organoids carrying or not carrying an immune feature. The application also provides a culture method of the osteosarcoma organoids carrying the immune feature. The osteosarcoma organoids are cultured by using the culture method and the kit, the culture period is short, the stability is high, the in situ tumor heterogeneity can be reserved, the tumor microenvironment immune feature is stable, and the kit can be used for high-throughput drug screening, target gene identification, immunotherapy drug screening, oncolytic virus killing experiment, omics research such as single cell sequencing, and animal model construction. The application fills the blank of the interstitial-derived osteosarcoma organoid immune co-culture, and has a wide application prospect in the field of osteosarcoma basic research and clinical diagnosis and treatment.

Provided herein are methods of treating a subject suffering from multiple myeloma by administering a triplet therapy of carfilzomib, dexamethasone, and an antibody that specifically recognizes CD38.